Group 1 - The company announced a share repurchase plan with a total expected amount between 70 million and 131.58 million RMB, with a repurchase price not exceeding 7.31 RMB per share [1] - The repurchase period is set from March 14, 2025, to March 14, 2026, and the shares will be used for the 2025 restricted stock incentive plan [1] - As of July 31, 2025, the company has repurchased a total of 16.299951 million shares, accounting for 1.25% of the total share capital, with a total expenditure of 80.2576 million RMB [2] Group 2 - The highest repurchase price recorded was 5.22 RMB per share, while the lowest was 4.69 RMB per share [2] - The total share capital increased from 1,308,916,414 shares at the end of June 2025 to 1,308,927,729 shares at the end of July 2025 due to the conversion of the company's convertible bonds [2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [2]
南京医药: 南京医药关于以集中竞价交易方式回购公司股份的进展公告